GAL/GALR epigenetic variants are excellent markers for the prognosis prediction of patients suffering from HNSCC [193,194]; thus, the GAL1R methylation status could be a biomarker for predicting HNSCC clinical outcomes. This evidence concerns the gene GAL and head and neck squamous cell carcinoma.